Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients
about
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsThe resistance mechanisms of proteasome inhibitor bortezomib.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomibIDENTIFICATION OF PROTEASOME ALPHA6 SUBUNIT ASSOCIATED WITH DELTAMETHRIN RESISTANCE IN Drosophila melanogaster Kc CELLS.Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.Molecular chess? Hallmarks of anti-cancer drug resistanceNoncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDifferential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with intHigher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Proteasome inhibitors in acute leukemia.The role of P-glycoprotein in drug resistance in multiple myeloma.Mechanisms and therapeutic potential of inhibiting drug efflux transporters.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Molecular mechanisms of acquired proteasome inhibitor resistance.Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.(Immuno)proteasomes as therapeutic target in acute leukemia.Positioning of proteasome inhibitors in therapy of solid malignancies.Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
P2860
Q33742779-EEC69E11-791C-4FAF-9BE6-902371D16EA6Q34010999-7CFE31D0-3958-4297-901C-E8CF618ADBA0Q34218976-C04720B6-B256-4D19-ACB3-414A0A1ACE0EQ34256126-E9F4983E-85AB-44A5-8FFB-02A9F975E113Q34317307-60903D62-E217-4B93-AC20-64EBD534125EQ35893499-F050D8F7-BACE-4EB4-9219-820BF156AAB9Q36216250-36220A7A-1080-4107-92E2-65E4D74B6134Q36240941-DA4339DF-C041-4EA2-BF36-6796AF71EC49Q36691554-EF9B2B13-59D7-48C0-A934-A4694B310EE2Q36717999-6A04AA48-A3E5-48C1-9716-36ACEC9121C5Q36916869-4DAEEDA9-4A1C-44BB-AD45-9465669F26F0Q37132862-CD549861-1545-46B0-8D39-130415DB3516Q37193232-64D80D3E-2D73-4BDB-AB11-4C86DD14D5EFQ37377911-3A1AB4FE-F755-4937-8F68-54ABEEC289A7Q37688848-42510C25-3C16-47A4-B26F-924515F158F4Q38019864-226AFECA-F1D5-4F9A-85DD-C3A56BBAA146Q38088003-15F27741-CCAD-4492-A57F-C5A7EF2079BAQ38200143-0471821F-8CC5-4B17-8CB7-DAF54D821D45Q38388828-F5660497-8244-41B5-A50E-4E9179F2BA3FQ38427697-F284B022-7E35-47D1-BA2D-29017F7ECEE1Q38932086-02CC7386-1080-4055-BAE2-42A605871C5CQ38986185-14B13DD3-FC68-4EE1-84A5-2BC6C37E8AE6Q39278628-AC682366-5C4F-487C-A5CA-DC6071DDF295Q41554672-2C36CB02-5A02-4A57-90B9-01898209CFE6Q41860750-FB558B29-AA0F-496A-BD11-615076ED1B2AQ43097558-F0D6A4F4-C923-4CD4-8DB7-B0CE486CEB95Q47131929-2BFEFDAA-16D2-4C4F-8CB9-B124B26BF4FDQ47353792-ECEE573D-F1BB-4E3C-9B1A-49B5C4071121Q48184671-D8F17BCF-9FDF-47C7-A0FF-C210438D4361Q48943059-E883A8CE-487A-4825-B2A8-6A5C1E8CDFEB
P2860
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inactivating PSMB5 mutations a ...... lear blood cells from patients
@en
Inactivating PSMB5 mutations and P-glycoprotein
@nl
type
label
Inactivating PSMB5 mutations a ...... lear blood cells from patients
@en
Inactivating PSMB5 mutations and P-glycoprotein
@nl
prefLabel
Inactivating PSMB5 mutations a ...... lear blood cells from patients
@en
Inactivating PSMB5 mutations and P-glycoprotein
@nl
P2093
P356
P1476
Inactivating PSMB5 mutations a ...... lear blood cells from patients
@en
P2093
Ben A C Dijkmans
Christopher J Kirk
Debby den Uyl
Elena T Chan
George L Scheffer
Gerrit Jansen
Godefridus J Peters
Joost W van der Heijden
Rik J Scheper
P304
P356
10.1124/JPET.111.187542
P407
P577
2012-01-10T00:00:00Z